Stimulated by the finding that CSF-1R antagonist enabled anti-PD-1 antibody to control tumor growth in the transgenic neuroblastoma mouse model (TH-MYCN), we aimed to dissect the key mechanistic events underlying this combination treatment. The gene discussed is CSF1R; the disease is neoplasm.